Celularity's Strategic Partner Announces Groundbreaking For Stem Cell & Regenerative Medicine Center In Asia Pacific
Celularity's Strategic Partner Announces Groundbreaking For Stem Cell & Regenerative Medicine Center In Asia Pacific
- Celularity is collaborating with its strategic partner, Genting Berhad, to bring Celularity placenta-derived allogeneic stem cell therapeutics to the Asia Pacific region
-
Genting Berhad announced groundbreaking on a new, state-of-the-art wellness and health center in Bali, Indonesia, that will utilize Celularity products
-
Strategic partnership positions Celularity to be a key supplier of innovative stem cell and regenerative medicine products for use in the Asia Pacific region
- Celularity正在與其戰略合作伙伴雲頂有限公司合作，將Celularity胎盤衍生的異基因幹細胞療法引入亞太地區
- 雲頂有限公司宣佈在印度尼西亞巴厘島動工建造一座最先進的全新康體和健康中心，該中心將使用Celularity產品
- 戰略合作伙伴關係使Celularity成爲亞太地區使用的創新幹細胞和再生醫學產品的主要供應商
FLORHAM PARK, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company, today announced that its strategic partner, Genting Berhad, has broken ground on Fontaine Vitale, a state-of-the-art stem cell and regenerative medicine facility in the Sanur Special Economic Zone located in Bali, Indonesia. Fontaine Vitale will offer world-class cell therapies focused on wellness, aesthetics, and regenerative medicine to both local and international patients using placenta-derived stem cells manufactured by Celularity in its US facility, according to Genting Berhad's press release. The new center is expected to commence commercial operations towards the end of 2026.
新澤西州弗洛勒姆公園，2024年11月20日（環球新聞專線）——再生和細胞醫學公司Celularity Inc.（納斯達克股票代碼：Celu）（「Celularity」）今天宣佈，其戰略合作伙伴雲頂有限公司已在位於印度尼西亞巴厘島的沙努爾經濟特區破土動工，這是一家位於印度尼西亞巴厘島的沙努爾經濟特區最先進的幹細胞和再生醫學設施。根據雲頂有限公司的新聞稿，Fontaine Vitale將使用Celularity在美國工廠生產的胎盤衍生幹細胞，向本地和國際患者提供專注於健康、美學和再生醫學的世界一流的細胞療法。新中心預計將於2026年底開始商業運營。
